TABLE II.
Microfluidic | Size | Pressure | Temperature | ||
---|---|---|---|---|---|
design | Nanoparticle | (nm) | (MPa) | (°C) | Reference |
Co-flow | Palladium (Pd) nanocrystal | 3.6 ± 0.6 | 25 | 100 | Gendrineau et al.49 |
Co-flow | Poly(3-hexylthiophene) (P3HT) nanoparticle | 36 ± 8 | 10 | 40 | Couto et al.50 |
47 ± 12 | 8 | 50 | |||
Co-flow | Tetraphenylethylene (TPE) nanoparticle | 9 ± 3 | 10 | 40 | Jaouhari et al.80 |
Co-flow | Fluorescent organic nanoparticle | 16 ± 4 | 10 | 40 | Jaouhari et al.46 |
T-junction | Polyvinyl alcohol (PVA) nanoparticle | 10–20a | 8.5–12 | 36.85 | Murakami and Shimoyama51 |
T-junction | Ibuprofen/PVA nanoparticleb | 231 ± 31 | 8.5–12 | 36.85 | Murakami and Shimoyama52 |
T-junction | Timolol maleate (TM)-loaded liposome | 80–3000c | 10 | 40 | Murakami et al.54 |
T-junction | PEGylated liposome | 270–417d | 10 | 40 | Akiyama et al.53 |
T-junction | Stearic acid solid lipid nanopariticle | 20–150e | 8.5–20 | 40 | Wijakmatee et al.81 |
Depending on the degree of PVA hydrolyzed.
Ibuprofen/PVA nanoparticles were functionalized by chitosan.
Depending on the co-solvent (ethanol) flow rate.
Depending on the ratio of PEG:lipid.
Depending on the pressure and total flow rate of water and oil phases.